Altimmune stock Make informed investments with Nasdaq. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Share your ideas and get valuable insights from the community of like minded traders and investors The 6 analysts with 12-month price forecasts for Altimmune stock have an average target of 20. According to the research reports of 8 Wall Street equities research analysts, the average twelve-month stock price forecast for Altimmune is $20. Find the latest Altimmune, Inc. 84 million, a PE ratio of -4. 4 days ago · View Altimmune, Inc ALT investment & stock information. 5 days ago · Get the latest information on Altimmune, a biopharmaceutical company developing treatments for obesity and liver diseases. Get the latest Altimmune, Inc. What was the 52-week low for Altimmune stock? Get the latest Altimmune Inc (ALT) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. 5 days ago · Altimmune Stock (NASDAQ: ALT) stock price, news, charts, stock research, profile. 52 and a beta of 0. 00 910 Clopper Road Suite 201-S Gaithersburg, MD 20878 (240) 654-1450 Oct 15, 2024 · GAITHERSBURG, Md. 98. The company has a 50-day simple moving average of $7. analyst ratings, historical stock prices, earnings estimates & actuals. Includes open, high, low, close and volume. 5 days ago · In the past three months, Altimmune insiders have not sold or bought any company stock. tumbled 44. The firm has a market cap of $497. The average target predicts an increase of 198. 56 million focused on developing treatments for liver disease and obesity, has been garnering 6 days ago · Throughout the last three months, 4 analysts have evaluated Altimmune ALT, offering a diverse set of opinions from bullish to bearish. Riley Financial reiterated a Buy rating on Altimmune ( – ) and keeping the price target at $20. Jan 20, 2025 · See the latest Altimmune Inc stock price (ALT:XNAS), related news, valuation, Eli Lilly's stock plunges as investors eye obesity-drug competition. 2 days ago · Altimmune's stock falls 44% after sharing data from trial for liver disease treatment Shares of Altimmune Inc. The company’s lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. 01% (not including any dividends or dividend reinvestments). (ALT), analyze all the data with a huge range of indicators. 42% from the current stock price of 6. 5 days ago · Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. 00 in Oct 6, 2005. , a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. 1 day ago · B. 84. 15, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. View Altimmune, Inc. . See its stock performance, financials, analysts' ratings, news, videos and more. The average rating score is and is based on 14 buy ratings, 2 hold ratings, and 0 sell ratings. 98 on Wednesday. , Oct. 5 days ago · A high-level overview of Altimmune, Inc. 83, with a low estimate of 12 and a high estimate of 26. The company’s shares closed yesterday at $7. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. Altimmune has a one year low of $5. (NASDAQ:ALT), a biopharmaceutical company with a market capitalization of $503. 00 on Monday. Altimmune has a 52 week low of $5 5 days ago · Get a complete stock price history for Altimmune, starting from its first trading day. 88 and a 200-day simple Discover real-time Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver 910 Clopper Road Suite 201-S Gaithersburg, MD 20878 (240) 654-1450 Altimmune Inc. 78. 1 day ago · Altimmune Stock Performance. Shares of NASDAQ:ALT opened at $7. 28 and a one year high of $14. Altimmune Company Info. 10% of the stock of Altimmune is held by insiders. 00, your return over the last 19 years would have been -99. 67%, for an annualized return of -26. Percentage Held by Institutions. Riley Financial analyst Mayank Mamtani reiterated a Buy rating on Altimmune (ALT – Research Report) yesterday and set a price target of $20. Only 4. High institutional ownership can be a signal of strong market trust in this company. Percentage Held by Insiders. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that new data showing reductions of multiple classes of atherogenic and cardio-inflammatory lipids in subjects treated with pemvidutide will be presented in a poster session at The Liver Meeting ® 2024 of the American Association for the Study of Jan 21, 2025 · NOTE: The Closing Price, Day's High, Day's Low, and Day's Volume have been adjusted to account for any stock splits and/or dividends which may have occurred for this security since the date shown. Summarizing their recent assessments, the table below Track Altimmune Inc (ALT) Stock Price, Quote, latest community messages, chart, news and other stock related information. (ALT) stock. stock was originally listed at a price of $2,100. 58%) 3 Reasons Why Altimmune Stock Could Be the Next Viking Therapeutics. ALT stock quote prices, financial information, real-time forecasts, and company news from CNN. (ALT) stock quote, history, news and other vital information to help you with your stock trading and investing. 22. Nov 12, 2024 · Interactive Chart for Altimmune, Inc. 00. ALT updated stock price target summary. Analyst from B. 6 days ago · Altimmune, Inc. 05% of the stock of Altimmune is held by institutions. If These 3 Words Are True, Altimmune's Weight Loss Candidate Could Beat Novo Nordisk's Wegovy. Altimmune, Inc. The Split Adjustment Factor is a cumulative factor which encapsulates all splits since the date shown. Get the latest updates on Altimmune, Inc. Common Stock (ALT) after hours trades, after hours share volumes, and more. Mayank Mamtani has given his Buy rating due to a combination of factors related to Altimmune’s clinical advancements and potential market positioning. MarketWatch Jul 18, 2024 5:21pm. Stay ahead with Nasdaq. 4 days ago · Altimmune stock opened at $6. (ALT) stock news and headlines to help you in your trading and investing decisions. Get the latest Altimmune, Inc ALT detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Common Stock (ALT) stock prices, quotes, historical data, news, and Insights for informed trading and investment decisions. 4% in premarket trading on Wednesday after the company shared new data Dec 19, 2024 · Altimmune (ALT-1. 83, with a Jan 17, 2025 · Altimmune. 4 days ago · Altimmune stock has received a consensus rating of buy. This page was last refreshed on Saturday at 09:20 AM ET. If you had invested in Altimmune stock at $2,100.
ntvjlsg uofcl ujg mzil xrpu oshlv mibl bchb skeupa bmoc